509 related articles for article (PubMed ID: 27951522)
1. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
[TBL] [Abstract][Full Text] [Related]
2. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
[TBL] [Abstract][Full Text] [Related]
3. Brain lesion distribution criteria distinguish demyelinating diseases in China.
Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
[TBL] [Abstract][Full Text] [Related]
4. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
Hyun JW; Huh SY; Shin HJ; Woodhall M; Kim SH; Irani SR; Lee SH; Waters P; Kim HJ
Mult Scler; 2019 Apr; 25(4):585-590. PubMed ID: 29512413
[TBL] [Abstract][Full Text] [Related]
7. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
[TBL] [Abstract][Full Text] [Related]
10. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
Matthews L; Marasco R; Jenkinson M; Küker W; Luppe S; Leite MI; Giorgio A; De Stefano N; Robertson N; Johansen-Berg H; Evangelou N; Palace J
Neurology; 2013 Apr; 80(14):1330-7. PubMed ID: 23486868
[TBL] [Abstract][Full Text] [Related]
11. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
Cai MT; Zheng Y; Shen CH; Yang F; Fang W; Zhang YX; Ding MP
Mult Scler; 2021 May; 27(6):871-882. PubMed ID: 32672091
[TBL] [Abstract][Full Text] [Related]
14. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
Front Immunol; 2020; 11():1188. PubMed ID: 32625206
[TBL] [Abstract][Full Text] [Related]
16. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
[TBL] [Abstract][Full Text] [Related]
17. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
Carnero Contentti E; Rojas JI; Criniti J; Lopez PA; Daccach Marques V; Soto de Castillo I; Tkachuk V; Marrodan M; Correale J; Farez MF; Kim HJ; Hyun JW; Messina S; Mariano R; Rocca MA; Cacciaguerra L; Filippi M; Palace J; Juryńczyk M
Mult Scler Relat Disord; 2022 May; 61():103778. PubMed ID: 35452969
[TBL] [Abstract][Full Text] [Related]
18. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
Cortese R; Battaglini M; Prados F; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Wuerfel J; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Callegaro D; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira A; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Proebstel AK; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Carmisciano L; Sormani MP; Barkhof F; De Stefano N; Ciccarelli O;
Brain; 2023 Jun; 146(6):2489-2501. PubMed ID: 36515653
[TBL] [Abstract][Full Text] [Related]
19. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
20. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
[Next] [New Search]
